Professor and Research Cluster Coordinator
Department: Biochemistry and Microbiology; Pediatrics
Research Cluster: Infectious and Immunological Diseases
Office: BBSC 336-S | Laboratories: BBSC 315 and 331
Phone: (304) 696-7356 | Fax: (304) 696-7207
The following article was taken from the website of the Huntington Herald-Dispatch. It highlights the work of many of the professors researching in the Biomedical Sciences Graduate Program at Marshall University.
CHARLESTON – There is no shortage of exciting research going on in the laboratories at Marshall University. Scientists and technicians from this region and from around the world have converged at Marshall to do research on topics such as heart disease, cancer and many others. Their research might one day save a life, or at least make someone’s life better.Their work might not be easy for the layperson to understand, but university and business officials are working diligently to help ensure the work West Virginia’s scientists are doing also results in three simple words: dollars and cents.
The economic potential for bioscience research in West Virginia is still hard to grasp, but there is a lot happening already and much optimism for the future.
“We are looking at a pipeline of commercial opportunities coming out of research being done in West Virginia,” said John Maher, vice president for research at Marshall University.
Officials from Marshall, West Virginia University and several business related to the bioscience industry gathered last week for the Second Annual West Virginia Bioscience Summit, held Wednesday at the Marriott Hotel in Charleston.
“This conference is a unique opportunity for people interested in the biosciences to get together and get an update on the status of the industry over the last year,” said Derek Gregg, CEO of Vandalia Research here in Huntington and chairman of BioWV.
The summit featured presentations from West Virginia University, Marshall, Mountwest Community & Technical College, Vandalia Research, Protea, TRAX Biodiscovery, and others to talk about what their organizations have accomplished over the past year.
“This also allows new collaborations and partnerships to be developed,” Gregg said. “Additionally, we had substantial representation from out-of-state organizations looking for new partners and opportunities.”
The biosciences in West Virginia are growing rapidly and the state’s credibility is increasing in the United States and around the world, Gregg said.
“We are spinning out new enterprises, and some of those enterprises are raising capital and hiring people,” he said. “Protea was recently recognized world-wide as having one of the top 10 innovations of 2011. They now employee over 50 people.”
Four companies are now being housed and supported at Vandalia Research’s facility in Huntington, including Progenesis, Maven Analytical and Parabon Nanolabs. These companies sell to pharmaceutical, chemical and diagnostic companies around the world, Gregg said.
Marshall has a lot of exciting research under way right now, said Dr. Richard Niles, senior associate dean for Research and Graduate Education at Marshall’s Joan C. Edwards School of Medicine.
Here are some examples:
Dr. Piyali Dasgupta is looking at lung cancer and at how capsaicin, the hot stuff in chili peppers, which inhibits the growth of cancer cells in animals.
Dr. Nalini Santanam is looking at the effects of age and gender on the fat around the heart, and at oxidative stress in endometriosis.
Dr. Eric Blough of the Center for Diagnostic Nanosystems has 16 different projects going on.
Dr. Jingwei Xie is working with glass tubes for bone tissue engineering.
Dr. Hongwei Yu is working on genetic regulation of biofilm formation by pseudomonas aeruginosa, a bacterium that can cause disease in animals.
Dr. Pier Paolo Claudio is doing cancer research that involves gene therapy using microbubbles for delivery of a virus.
Niles is co-founder with Yu on the biotech business Progenesis, which provides natural, biodegradable polymers for industrial and medical applications through genetic engineering of bacteria. He talked about his experience of starting a biotech business at Wednesday’s Summit.
The universities are working to help others make discoveries and translate them into businesses as well. And the state is helping.
Both Marshall and WVU have received state funding for research through the West Virginia Research Trust Fund, providing $35 million to WVU and $15 million to Marshall for research, provided they come up with a match. WVU has reached its goal and Marshall has $9.4 million secured in gifts and pledges and the potential to reach, or go beyond, its goal very shortly, Maher said.
The universities also have attracted a lot of federal grant funding, all of which rolls over in the local economies as it provides high-paying jobs that attract scientists to the community.
Also in Huntington, Mountwest Community and Technical College is hard at work training students to become biological technicians, environmental science and environmental protection technicians, biomedical laboratory technicians and health technicians, said Jean Chappel, dean of Allied Health at MCTC.
It has a state-of-the-art lab where they can learn molecular diagnostics, tissue culturing, electrophoresis and use a digital fluorescent microscope.
MCTC also works on community outreach, not only targeting science teachers but high school and middle school students. It has a camp where “they’re isolating DNA just like they do on CSI,” Chappel said.
Over the course of one week, students’ aspirations might change from working a minimum wage job to becoming a PhD scientist, she said.
The college wants to help the state have “a well-rounded, educated workforce that wants to stay right here,” Chappel said.
It’s great to see several different parties working toward the same goal, said Laura Gibson, deputy director of the Mary Babb Randolph Cancer Center and a professor at WVU.
“The greatest measure of our success is really how we partner,” she said.
Capital formation, attraction and retention of talent, and community development are focus areas for Bio West Virginia in the coming years, Gregg said.
“Incentivizing investment in this area is critical,” he said, “Nearly all of our neighboring states have a program or programs for stimulating investment in high-technology, high-growth, high-RISK businesses to stimulate economic development. West Virginia has had programs in the past that were successful in helping companies raise capital, such as the High Growth Business Investment Tax Credit.
“BioWV is strongly encouraging the renewal of this and other programs that can help companies transition from the campus to the market.”
Ginny Painter with the Marshall University Research Corporation (MURC) released the following article. It may be found below and at http://www.eurekalert.org/pub_releases/2011-03/murc-cff032811.php.
HUNTINGTON, W.Va. – The Cystic Fibrosis Foundation has awarded a Marshall University scientist a two-year, $194,400 grant.
The grant to Dr. Hongwei Yu, professor in the Department of Biochemistry and Microbiology at the university’s Joan C. Edwards School of Medicine, will help further his lab’s work to explore the factors that control the overproduction of mucus in the lungs of cystic fibrosis (CF) patients.
According to Yu, chronic bronchial pneumonia caused by the bacterium Pseudomonas aeruginosa is a life-threatening condition for patients with CF.
“During these infections in CF patients, the bacterium is capable of producing copious amounts of alginate—a thick, sugar-like polymer that plugs the airways, making breathing difficult,” he said. “The alginate also helps form a thick, slimy ‘biofilm’ around the colonies of bacteria, protecting them from the body’s immune defense mechanisms and making antibiotic treatment less effective.”
Yu said the long-range goal of his research is to better understand the mechanisms of how this bacterium regulates production of the alginate biofilms in order to develop a more effective treatment option to inhibit or suppress the formation of alginate biofilms in the lungs of CF patients.
“For this project, we will be accessing the relevance of two newly identified proteins that act as alginate regulators. Once the mechanisms controlling alginate production are fully understood, it may be possible to improve treatment of these bacterial infections in CF patients by modulating or suppressing that production,” he added.
Dr. John Maher, Marshall’s vice president for research, congratulated Yu and praised him and his team for obtaining the grant.
“Dr. Yu’s work is an excellent example of the vital research here at Marshall University that can affect the health and welfare of people everywhere. Research in his lab has the potential to have a real impact on the quality of life for people with cystic fibrosis,” said Maher.
Maher also noted that Yu’s research has had a regional economic development impact, saying his work has led to a patent and the development of Progenesis Technologies LLC, a West Virginia-based biotech research and development company. A second patent is pending.
Prior to joining Marshall in 1999, Yu was on the research faculty of the University of Michigan Medical School. In addition to the Cystic Fibrosis Foundation, his work has been funded by NASA, the National Institutes of Health, the U.S. Department of Agriculture and the West Virginia NASA Space Grant Consortium.
The Cystic Fibrosis Foundation is the world’s leader in the search for a cure for cystic fibrosis. The foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of foundation support. Based in Bethesda, Md., the foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, go to www.cff.org.